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Alzheimer’s disease (AD) includes several hallmarks comprised of amyloid-b (Ab)
deposition, tau neuropathology, inflammation, and memory impairment. Brain
metabolism becomes uncoupled due to aging and other AD risk factors, which
ultimately lead to impaired protein clearance and aggregation. Increasing evidence
indicates a role of arginine metabolism in AD, where arginases are key enzymes in
neurons and glia capable of depleting arginine and producing ornithine and polyamines.
However, currently, it remains unknown if the reduction of arginase 1 (Arg1) in myeloid cell
impacts amyloidosis. Herein, we produced haploinsufficiency of Arg1 by the hemizygous
deletion in myeloid cells using Arg1fl/fl and LysMcreTg/+ mice crossed with APP Tg2576
mice. Our data indicated that Arg1 haploinsufficiency promoted Ab deposition,
exacerbated some behavioral impairment, and decreased components of Ragulator-
Rag complex involved in mechanistic target of rapamycin complex 1 (mTORC1) signaling
and autophagy. Additionally, Arg1 repression and arginine supplementation both impaired
microglial phagocytosis in vitro. These data suggest that proper function of Arg1 and
arginine metabolism in myeloid cells remains essential to restrict amyloidosis.
Keywords: Alzheimer’s disease, neuroinflammation, arginine metabolism, macrophage, microglia, phagocytosis,
cognition, Tg2576
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INTRODUCTION
Arginine metabolism associates with numerous biological
pathways. The impact of arginine levels and arginine signaling
warrants further consideration in Alzheimer’s disease (AD)
because of its high demand for multiple metabolic pathways and
recent discoveries of mTORC1 activation associated bona fide and
putative arginine sensors that locate at the lysosome [SLC38A9 (1),
TM4SF5 (2)], cytoplasm [CASTORs (3)], and plasma membrane
[GPRC6A (4)]. In this respect, properly coordinated arginine
metabolism remains critical for linear coupling of signaling
events linked to nutrients/amino acids sensing and mTORC1
regulation and could be particularly important for immune cells
during neurodegeneration. In addition to arginine’s role as a
substrate for protein synthesis and arginine sensors, at least five
enzymes catabolize arginine including arginase 1, 2 (ARG1,ARG2),
nitric oxide synthases 1, 2, 3 (NOS1, 2, 3), arginine decarboxylase
(ADC), arginine/glycine amidinotransferase (AGAT1), and
arginyltransferase (ATE1), suggesting a critical role for numerous
biological processes (5, 6). Therefore,Arg1may control the degree
to which proteolysis occurs, protein turnover, and thus impact
proteinopathies. Dysmetabolism of arginine and polyamines were
among the most altered in mild cognitive impairment (MCI) and
AD patient blood samples (7–9), cerebral spinal fluid (CSF) (9, 10)
and postmortem brain tissues (11–14). Alterations in arginine
metabolism were also observed in mouse models of Ab and tau
deposition (15–19) and in vitro models (20). However,
experimental manipulations and animal models concluded
different outcomes regarding arginine metabolism in
neuropathology (16, 17). Other reports indicated that a potential
rare arginase 2 allele was linked to an increased risk of AD (21).
These reports signify a relationship between arginine metabolism
and AD.
Balanced compartmental arginine levels are necessary for
normal physiology and likely require cell type specific demands
for proper functioning. Several reports link Arg1 to microglia/
monocyte wound repair and phagocytosis (22, 23). A previous
study by our group showed that Arg1 overexpression decreased
neuroinflammation and tau pathology in a tauopathy mouse
model (17). Another group reported Arg1 positive microglia
were responsible for reducing Ab plague deposition during
sustained neuroinflammation in an amyloidosis mouse model
(24). Monocytes and other peripheral myeloid cells were found
to infiltrate the brain and home to Ab deposits, thus ameliorated
amyloidosis pathology (25, 26). However, the impact on Ab
deposition following the myeloid-specific deletion of Arg1
remains unknown. We determined to assess how the
haploinsufficiency of Arg1 in myeloid cells impacts the brain
during amyloidosis using conditional LysMcre deletion in APP
Tg2576 transgenic mice. We performed immunohistochemical
analysis, mouse behavioral assessments, and biochemical
analysis in mice of amyloidosis and Arg1 haploinsufficiency.
We also performed in vitro microglia phagocytosis assays
following Arg1 reduction and arginine supplementation. Our




The Tg2576 mice carrying a heterozygous allele for human
APP KM670/671NL Swedish mutation and non-transgenic
(nTg) littermates were bred at the University of South Florida
under Dave Morgan and Marcia Gordon. Cre-recombinase
mice (B6.129P2-Lyz2tm1(cre)/fo/J; LysMcre promoter, Stock
No: 004781) and Arg1 mice (C57BL/6-Arg1tm1Pmu/J (Arg1fl),
Stock No: 008817) were purchased from the Jackson
Laboratory. The APP Tg2576 mice (APP+/−), Arg1 floxed
mice (Arg1fl/fl), and LysMcreTg/+ were bred according to the
published protocol (27). Therefore, we created four groups
including: nTg/Arg1+/+/LysMcreTg/+ (n = 17, nine males/
eight females), nTg/Arg1fl/+/LysMcreTg/+ (n = 22, 10 males/12
females), APP+/−/Arg1+/+/LysMcreTg/+ (n = 8, four males/four
females, APP+/−/Arg1fl/+/LysMcreTg/+ (n = 10, seven males/
three females).
Behavioral Testing
All mice were aged at 15 months and subsequently exposed to a
series of behavioral tasks to evaluate cognition and general activity.
All tests were executed in order of increasing stress with appropriate
break time between tests to avoid any lingering effects of previous
experimental conditions. The experimenter was blinded to the data
and experimental groups. The video tracking software ANY-maze
(version 4.99, Stoelting Company, Wood Dale, IL) was used.
Open Field
Open field test (Ugo Basile S.R.L., Italy) was performed to
measure general ambulatory activity and anxiety-related
behaviors. After a 30-min procedure room acclimation period,
mice were allowed to investigate the 44 cm2 maze for 15 min
while being recorded by ANY-maze. The locomotive activity was
measured for total distance traveled and total time immobile.
Anxiety-related behavior was measured by time in the center
zone. Increased thigmotaxis indicates anxiety-related behavior
and suggests an increased anxiety level.
Y-Maze
The Y-maze test (Ugo Basile S.R.L., Italy) was used to calculate
spontaneous alternation to measure spatial working memory and
anxiety. Mice were permitted to freely travel the maze (35 cm ×
5 cm × 10 cm; L × W × H) for 5 min, while all movements
recorded by ANY-maze. Alternation occurs if a mouse entered a
different arm during three consecutive entries. The percentage of
alternation was calculated (number of alternations divided by the
total number of entries minus two). The decreased percentage of
alternations suggests impaired working memory.
Radial Arm Water Maze
We performed a radial arm water maze (RAWM) based on the
previous protocol with minor changes (28). In brief, six
swimming arms are extending from the center. Only the goal
arm contains the escaping platform at the end. Each arm is
associated with an obvious visual cue in the surrounding
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environment. On day 1, mice were trained with constant
alternating between visible and hidden platforms with the
same goal arm for 15 trials. On day 2, mice were exploring the
arms with only the hidden platform located at the same goal arm
as day 1 for 15 trials. On day 3 (reversal), the platform was
hidden at the goal arm opposite to that used on day 1 and day 2
and mice explored the arms for 15 trials. One error is counted if
the mouse explores an arm that is different from the goal arm. An
approximate average cohort size of 16 per day was designed and
mice in the same cohort ran through each trial sequentially. The
average and total errors for three continuous trials are calculated
into five blocks over three days.
Aversive Conditioning
We performed contextual and cued fear conditioning test to
measure the animal ability to learn and recollect links between
environmental cues and aversive experiences. For this test, an
auditory conditioned stimulus (CS, white noise, 70 dB) was
accompanied by an unconditioned aversive stimulus (US, a
mild foot shock, 0.5 mA) in a novel environment. On day 1
(Training), we placed mice in the fear conditioning apparatus for
180 s, then a 30 s CS was delivered with the US on the metal floor
grid during the final 2 s. The training comprised of two CS,
paired with two US, with a 2 min interval in between. On day 2
(24 h post-training), we placed mice in the apparatus, with no
cues or stimulus (context fear conditioning), for 60 min while
monitored for freezing. Directly after contextual testing, we
placed the mice into a novel context and exposed them to CS
for 180 s (cued fear conditioning). Freezing behavior related to
both contextual and cued stimuli were used to assess learning
and fear associated recall.
Immunohistochemistry
We performed immunohistochemistry on free-floating 25 µm
sections as previously described (29). At 16 months of age,
following all behavioral testing, mice were humanely
euthanatized using Somnasol (provided by USF vivarium) and
transcardially perfused with 0.9% normal saline. Post perfusion,
one hemisphere of the brain was fixed in 4% paraformaldehyde
in 100 mM phosphate buffer (pH 7.4) for 24 h while the
remaining hemisphere was dissected and stored at −80°C.
Cryoprotection was achieved by sequential immersion in 10,
20, 30% of sucrose for 24 h each. Using a sliding microtome,
brains were sectioned, placed in DPBS containing 100 mM
sodium azide (Sigma-Aldrich, #S2002), and stored at 4°C. The
primary antibodies and reagents were used: rabbit anti-b-
amyloid (Ab) 1-43 (Covance, #Sig-39145); rabbit anti-Ab 1-42
(Covance, #Sig-39142); rabbit Ab 1-40 (Covance, #Sig-39146);
rabbit anti-Ab 1-38 (BioLegend, #808603); rabbit anti-IBA1
(Wako Chemicals, #016-26461); and rat anti-mouse CD68
(AbD Serotec, #MCA1957).
Detection of Congophillic Deposits
We performed Congo red histology as described previously (30).
Briefly, brain sections were mounted and submerged for 20 min
in alkaline sodium chloride, then incubated in 0.2% Congo Red
solution (Sigma-Aldrich), Congo Red staining kit #HT60-1KT)
for 30 min Sections were then rinsed in 95 and 100% ethanol,
cleared in xylene for 15 min, and coverslipped with DPX
mountant (Electron Microscopy Sciences). Statistical analysis
was performed for total, vascular, and parenchymal Ab loads.
Protein Preparation for Biochemical
Analysis
We prepared protein samples for ELISA and western blotting
from the frozen anterior cortex and posterior cortex as
previously described (17). Tissues were weighed and
resuspended in RIPA buffer (50 mM Tris pH 7.6, 140 mM
NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS) at 10%
wt/vol, containing a 1% vol/vol protease inhibitor cocktail
(Sigma-Aldrich, #P8340), phosphatase inhibitor cocktail
2 (Sigma-Aldrich, #P5726), phosphatase inhibitor cocktail 3
(Sigma-Aldrich, #P0044), and PMSF (Sigma-Aldrich,
#10837091001). Tissues were mechanically homogenized and
sonicated to obtain the whole cell lysate. An aliquot of the whole-
cell lysate was centrifuged for 30 min at 40,000 g (4°C).
Supernatant detergent soluble (S1) was collected. The resulting
pellet became a P1 fraction. The protein concentration of whole-
cell lysate and S1 fraction was measured by Pierce™ BCA Protein
Assay Kit (Thermo Fisher Scientific, Thermo Scientific™,
#23225) according to the manufacturer’s protocol. The P1
protein fraction was resuspended in 70% formic acid using
20% volume of whole-cell homogenate aliquot, then incubated
for 1 h at room temperature. Formic acid was buffered with 1M
Tris (pH 7.5) using 25% volume of formic acid. A final pH value
at 7.5 was adjusted using NaOH solution (50% w/w) to create the
detergent insoluble, formic acid (FA) fraction.
L-Arginine Quantification
Whole-cell lysate samples prepared from the mouse posterior
cortex were subjected to liquid chromatography-mass
spectrometry/mass spectrometry (LC-MS/MS) using a standard
curve of specific amino acid analytes. Quantification of L-
arginine was performed by Sanford Burnham Prebys (Orlando,
FL, USA).
Ab 40 and Ab 42 ELISA
We measured the concentrations of Ab 40 and Ab 42 from the
aforementioned detergent soluble S1 and detergent insoluble FA
P1 fraction of anterior cortex protein lysate using the Ab 1-40
and 1-42 specific sandwich ELISA kit (Mega Nano Biotech. FL,
USA). In brief, we coated each well of a 96 well plate with 50 µl of
goat anti-human Ab 1-42 antibody (MegaNano BioTech Inc.,
AB-001) diluted in 1× PBS at 10 mg/ml and incubated overnight
at 4°C. We washed the plate five times and blocked it in 200 ml
blocking buffer at 37°C for 1 h. After washing the plate, 50 ml
diluted detection antibodies anti-Ab 40 (MegaNano BioTech
Inc., Ab40-002) or anti-Ab 42 (MegaNano BioTech Inc., AB42-
002) were mixed with either 50 µl diluted peptide standard
solution or diluted samples in a preparation plate before
loading to the assay plate. Then we incubated the plates at 4°C
overnight. The next day, we washed first and then added 100 µl
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of diluted secondary antibody into each well and incubated for 45
minutes on an orbital shaker at room temperature. The plate was
then washed four times before applying the TMB peroxidase
substrate (Surmodics, Inc., TMBS-1000), then the plates were
incubated at room temperature for 10 min. The reaction was
ended by adding 100 ml/well of 0.4 M H2SO4. Absorbance at
450 nm was measured with a BioTek Synergy H4 microplate
reader. The final concentration was calculated based on
peptide standards.
Western Blotting
We performed western blotting analysis as previously described
(17). Briefly, 30 µg of detergent soluble S1 protein was loaded to
measure the relative abundance of the protein target. Protein
samples were loaded onto the Novex™ 4 to 20% Tris-Glycine
Plus 20-well Midi Protein Gels (1.0 mm, Thermo Fisher
Scientific, Invitrogen™, #WXP42020BOXA). For a given
probing target, all groups of mice were loaded to the same gel
including resolving, transferring, and exposure. The following
primary antibodies were used: Anti-Liver Arginase (abcam,
#ab124917), LAMTOR2 (Cell Signaling Technologies, #8145),
LAMTOR3 (Cell Signaling Technologies, #8168), LAMTOR4
(Cell Signaling Technologies, #12284), RagA (Cell Signaling
Technologies, #4357), and anti-b-actin antibody (Sigma-
Aldrich, #A5441). Densitometric analysis was performed using
AlphaEase software (Alpha Innoch, CA, US).
Quantitative Real-Time PCR
We extracted total mRNA from cryopreserved hippocampal
tissues using AllPrep DNA/RNA/Protein Mini Kit (QIAGEN,
#80004) according to the manufacturer’s protocol. For qRT-PCR
analysis, we probed the mouse Arg1 mRNA from the
hippocampal tissues of the aforementioned four mouse groups.
The cDNA was generated using the Superscript™ III First-
Strand Synthesis System (Thermo Fisher Scientific,
Invitrogen™, #18080051). The QuantiTect Primer® Assay
was used for mouse Arg1 gene transcripts (QIAGEN,
Mm_Arg1_1_SG, #QT00134288, Lot# 229462537; IDT, Actin,
Mm.PT.39a.22214843.g) along with SYBR® Green Quantitative
RT-qPCR Kit (Sigma-Aldrich, #QR0100-1KT). We used a
standard curve from a pool of all genotypes to span three logs
of dynamic range. Melt curve analysis was performed for primer
validation. We used the Opticon 2™ Real-Time PCR System
(v4.3, Bio-Rad) to detect amplicon.
Primary Microglial Culture
All cells were maintained in a humidified cell culture incubator
(Forma™ Series II 3110, Thermo Fisher Scientific, Thermo
Scientific™) with 5% CO2 at 37°C. Primary microglia from 6-
month-old non-transgenic rats (n = 6, three males/three females)
were dissociated as described previously except that we used rat
CD11b magnetic microbeads (Miltenyi Biotec, #130-105-634)
for the final isolation step (31). Primary microglia were plated at
1.0*106 cells/well on a 6-well plate and maintained in a complete
medium using DMEM/F-12 (Thermo Fisher Scientific, Gibco®,
#11320082), supplemented with 10% heat-inactivated fetal
bovine serum (Sigma-Aldrich, #12306C, Lot#17H093), 1%
GlutaMAX™-I (200 mM, Thermo Fisher Scientific, Gibco®,
#35050061), and 1% Penicillin–Streptomycin (10,000 U/ml,
Thermo Fisher Scientific, Gibco®, #15140122). For arginine
supplementation experiments, we added L-arginine (3 mM or
10 mM; Sigma-Aldrich, #W381918-1KG) at 24 h post-plating
primary microglia. The control cells were not supplemented with
excess L-arginine and kept at the arginine concentration (0.699
mM) in the basal medium. Then 48 h post L-arginine incubation,
we performed a pHrodo phagocytosis assay (see below).
Microglial Cell Line Culture
Highly aggressively proliferating immortalized (HAPI) rat
microglial cell line was purchased from MilliporeSigma
(#SCC103) and regularly split into a new 75 cm2 sterile flask
two to three times a week before reaching 80% confluence. HAPI
cells were grown in a complete medium using DMEM (Thermo
Fisher Scientific, Gibco®, #11965167), supplemented with 5%
heat-inactivated fetal bovine serum (Sigma-Aldrich, #12306C,
Lot#17H093), 1% GlutaMAX™-I (200 mM, Thermo Fisher
Scientific, Gibco®, #35050061), 1% MEM Non-Essential
Amino Acids Solution (100×, Thermo Fisher Scientific,
Gibco®, #11140050), and 1% Penicillin–Streptomycin (10,000
U/ml, Thermo Fisher Scientific, Gibco®, #15140122). For siRNA
transfection, we plated HAPI cells at 17 k cells/well on a 24-well
plate, then 48 h later when cells were 50–60% confluent, we
transfected with either siGLO green oligonucleotide transfection
indicator (Dharmacon, #D-001630-01)), non-targeting siRNA
(Dharmacon, #D-001210-05-05), or rat specific Arg1 siRNA
(Dharmacon, #M-091161-01-0005) using TransIT-X2®
Transfection Reagent (Mirus, #MIR6003) according to the
manufacturer’s protocol. We performed the pHrodo phagocytosis
assay 48 hours post-transfection.
Primary Macrophage Culture
Bone marrow derived macrophages (BMDMs) were isolated
from the femurs and tibias of nTg/Arg1+/+ mice, nTg/Arg1fl/fl
mice and nTg/Arg1fl/fl/LysMcreTg/+ mice at 3–6 months of age.
Bones were flushed with a syringe filled with cold washing media
(RPMI 1640 supplemented with 10% FBS and 1% penicillin/
streptomycin) to extrude bone marrow into a sterile falcon tube.
The bone marrow was then triturated three times using syringes
fit with 18 gauge needle and then centrifuged at 1,000 rpm for
5 min at 4°C. After decanting the supernatant, red blood cells
were lysed in lysis buffer (0.15 mol/L NH4Cl, 10 mmol/L
KHCO3, and 0.1 mmol/L Na2EDTA, pH 7.4) for 3 min. The
remaining cells were washed and pelleted in washing media, then
resuspended in BMDM differentiation media (RPMI 1640
supplemented with 1% penicillin/streptomycin, 1% HEPES,
0.001% b-mercaptoethanol, 10% FBS, and 20% supernatant
from sL929 cells-provides macrophage colony stimulating
factor) (32). BMDM cells were plated in T75 flasks at 5–8 ×
105 cells/ml. Cell culture media was changed on post days of 2, 4,
and 6, and then cells were re-plated at the density of 1 × 106 cells/
ml on day 7 in differentiation media without sL929 supernatant.
The following day, BMDMs were stimulated with LPS (100 ng/ml;
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Invitrogen) + IFN-gamma (20 ng/ml; eBioscience), IL-4 (20
ng/ml; eBioscience), or LPS (50 ng/ml) + IL-4 (20 ng/ml) in
Neuro-2a growth medium or differentiation media without
sL929 supernatant as previously described (33). Azithromycin
(AZM, Sigma PHR1088, 25 mM) was added to the BMDMs at the
time of stimulation. Unstimulated BMDMs were maintained in
the appropriate growth medium as controls. 24 h post
stimulation, the supernatant of the stimulated macrophages
(macrophage conditioned media) was collected and centrifuged
to remove the cell debris before being applied to Neuro-2a cells
for the measurement of neurotoxicity. BMDM cell lysates were
used to assess arginase activity using the QuantiChrom Arginase
Assay Kit (Bioassay Systems DARG-200) according to the
manufacture’s protocol.
Neurotoxicity Assay
Neuro-2a cells were cultured in growth media which contains
45% DMEM and 45% OptiMEM Reduced-Serum Medium (Life
Technologies) supplemented with 10% FBS and 1% penicillin/
streptomycin. Experiments were carried out using Neuro-2a cells
within 12 passages. Neurotoxicity was assessed after Neuro-2a
cells were seeded in 96-well plates at a density of 2 × 105 cells/ml
for 24 h in Neuro-2a growth media. Then Neuro-2a growth
media were replaced by different stimulated macrophage
conditioned media for 24 h. The cell viability was measured by
using MTT assay (Sigma-Aldrich) according to the manufacturer
instructions and as described previously (34).
Phagocytosis Assay
We performed the phagocytosis assay using the pHrodo™Green
E. coli BioParticles™ Conjugate for Phagocytosis kit (Thermo
Fisher Scientific, Invitrogen™, #P35366) according to the
manufacturer’s protocol. Briefly, we resuspended pHrodo™ E.
coli BioParticles® conjugates at 1 mg/ml buffer in sterile PBS (pH
7.4). We replaced the culture medium with the BioParticles®
suspension at 50 µl per well. Cells were incubated at 37°C for
90 min. We harvested single live cells using Trypsin-EDTA
(0.05%, Thermo Fisher Scientific, Gibco®, #25300054) and
measured the fluorescence using an Accuri® C6 flow cytometer
(BD Biosciences, Serial Number 2986).
Statistical Analysis
We performed all statistical analyses using SPSS (version 25.0, IBM Corp.,
Armonk, NY, USA) and generated all graphs using GraphPad Prism
(version 8.0.0, GraphPad Software, San Diego, CA, USA). Values were
represented as mean ± S.E.M. A two-way ANOVA of 2 × 2 factorial
analysis was used to determine simple main effects of APP transgene
genotype (APP+/−/LysMcreTg/+ vs nTg/LysMcreTg/+) and Arg1
haploinsufficiency genotype (Arg1fl/+/LysMcreTg/+ vs Arg1+/+/LysMcreTg/+)
as well as the interaction of the two genotypes, followed by pair-wise
comparisons for each genotype. An unpaired Student’s t-test was utilized
for two-group comparison (APP+/−/Arg1fl/+/LysMcreTg/+ vs APP+/−/Arg1+/
+/LysMcreTg/+), such as for measurements of Ab, which is not present in
non-transgenic animals. Two-way ANOVA followed by Dunnett’s or
Sidak’s multiple comparison tests were applied in analyzing experiments
using bone marrow derived macrophages.
RESULTS
Arg1 Insufficiency in Myeloid Cells
Promotes Diffuse Ab Deposition
To assess how Arg1 insufficiency in myeloid cells impacted
amyloidosis, we crossbred LoxP Arg1 (Arg1fl/fl) mice with
transgenic APP Tg2576 mice (APP+/−) to generate APP(+/−)/
Arg1(fl/−) and APP(−/−)/Arg1(fl/−) (non-transgenic, nTg) mice.
These mice were bred with the Cre deleter strain (LysMcreTg/+).
Mice knocked in allele of LysMcre harbor a Cre recombinase gene
inserted at the lysozyme 2 gene (Lyz2) initial ATG coding
sequence. The Lyz2 promoter targets myeloid lineage cells,
mostly macrophages, but also a certain percentage of microglia
(35–37). All groups contained one allele of the LysMcreTg/+. We
established four experimental groups of mice: non-transgenic/Arg1
sufficient mice (nTg/Arg1+/+/LysMcreTg/+), non-transgenic/Arg1
insufficient mice (nTg/Arg1fl/+/LysMcreTg/+), APP/Arg1 sufficient
mice (APP+/−/Arg1+/+/LysMcreTg/+), and APP/Arg1 insufficient
mice (APP+/−/Arg1fl/+/LysMcreTg/+). We confirmed the deficient
arginase 1 activity in primary macrophages of mice with Arg1flox
and LysMcreTg/+ (Supplementary Figure S1A, B).
To determine how Arg1 insufficiency impacts Ab deposition,
we measured total Ab, and forms with specific C termini ending
at Ab 38, Ab 40 and Ab 42 in the anterior cortex (ACX),
hippocampus (HPC), and entorhinal cortex (ECX) of the brain
in 16-month-old APP Tg2576 mice with Arg1 sufficiency and
insufficiency by immunohistochemistry. Non-transgenic mice
had undetectable levels of all Ab species (data not shown).
Overall, total Ab was increased in HPC (p = 0.043), ECX (p =
0.034) and trended toward an increase in ACX (p = 0.059) in
APP/Arg1 insufficient mice relative to APP/Arg1 sufficient mice
(Figures 1A, B, K). Ab 42 was significantly increased in APP/
Arg1 insufficient mice compared to APP/Arg1 sufficient mice in
all three brain regions (ACX, p = 0.038; HPC, p = 0.011; ECX, p =
0.005) (Figures 1C, D, L). However, we did not detect changes in
plaque load measured by Ab 40 (Figures 1E, F, M) or Ab 38
(Figures 1G, H, N). Furthermore, we measured compact plaques
using the histological stain Congo red and found no changes in
the ACX, HPC, and ECX regions between these two groups
(Figures 1I, J, O). Lastly, we measured Ab 42 and Ab 40 by
ELISA in both detergent soluble and insoluble (formic acid
soluble) fractions. We found increased Ab 42 in the detergent
soluble fraction (p = 0.048), but not in the formic acid fraction
(Figure 1P). No changes were detected for Ab 40 in ELISA
(Figure 1Q). Collectively, these data strongly suggest that Arg1
insufficiency during amyloidosis promotes diffuse Ab
42 deposition.
Arg1 Insufficiency During Amyloidosis
Increases Overall Microglial Activation
Next we measured microglial markers in various regions of the
brain by immunohistochemistry during amyloidosis and Arg1
insufficiency. We stained tissue sections for CD68 (Figures
2A–D) and IBA1 expression (Figures 2E–H). We found APP
mice showed a main effect of genotype with higher expression for
CD68 in ACX (p < 0.0001), HPC (p = 0.024) and ECX (p = 0.004)
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FIGURE 1 | Hemizygous deletion of Arg1 in myeloid cells of APP Tg2576 mice promotes Ab deposition. We performed immunohistochemistry staining for species
of Ab (total Ab, Ab 42, Ab 40, Ab 38) and Congophilic Ab deposition in the anterior cortex (ACX), hippocampus (HPC), and entorhinal cortex (ECX) of 15-month old
APP Tg2576 mice from two groups (APP+/−/Arg1+/+/LysMcreTg/+, APP+/−/Arg1fl/+/LysMcreTg/+). (A–J) Representative images for total Ab (A, B), Ab 42 (C, D), Ab 40
(E, F), Ab 38 (G, H), and Congo red (I, J) are presented. (K–Q) Quantification analysis of total Ab (K), Ab 42 (L), Ab 40 (M), Ab 38 (N), and Congo red (O) are
shown. ELISA was performed for Ab 42 and Ab 40 in the cortex. (P, Q) Quantification analysis of Ab 42 (P) and Ab 40 (Q) by ELISA for both detergent soluble
fraction and formic acid fraction. Quantification of Ab species and Congo red from staining was determined using six sections per mouse. For mice in each group,
n = 6–7 for APP+/−/Arg1+/+/LysMcreTg/+, n = 6–9 for APP+/−/Arg1fl/+/LysMcreTg/+. *p < 0.05; **p < 0.01. Unpaired Student’s t-test. Values represent mean ± SEM.
Scale bars represent 500 µm for images and 20 µm for insets.
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FIGURE 2 | Hemizygous deletion of Arg1 in myeloid cells increases microglia activation. We performed immunohistochemistry staining for IBA1 and CD68 in the
anterior cortex (ACX), hippocampus (HPC), and entorhinal cortex (ECX) of 15-month old mice from four groups (nTg/Arg1+/+/LysMcreTg/+, nTg/Arg1fl/+/LysMcreTg/+,
APP+/−/Arg1+/+/LysMcreTg/+, APP+/−/Arg1fl/+/LysMcreTg/+). (A–D) Representative images of IBA1 expression in ACX, HPC and ECX. (E–H) Representative images of
CD68 expression in ACX, HPC and ECX. (I), Quantification analysis of IBA1 images in (A–D). (J), Quantification analysis of CD68 images in (E–H). Quantification was
determined using 6 sections per mouse. For mice in each group, n=9-10 for nTg/Arg1+/+/LysMcreTg/+, n = 9–10 for nTg/Arg1fl/+/LysMcreTg/+, n = 7 for APP+/−/
Arg1+/+/LysMcreTg/+, n = 9 for APP+/−/Arg1fl/+/LysMcreTg/+. Asterisk sign (*) denotes statistical significance observed for main effect of APP genotype and associated
pairwise comparisons. Number sign (#) denotes statistical significance observed for main effect of Arg1 insufficiency genotype and associated pairwise comparisons.
*/#p < 0.05; **/##p < 0.01; ****p < 0.0001. Two-way ANOVA followed by pairwise comparisons. Values represent mean ± SEM. Scale bars represents 500 µm for
images and 50 µm for insets.
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compared to nTg mice (Figure 2I). Pairwise comparisons
between APP/Arg1 insufficient mice and nTg/Arg1 insufficient
mice were observed (ACX: p = 0.003; HPC: p = 0.035; ECX: p =
0.005; Figure 2I). There was a main effect of Arg1 insufficiency
genotype with increased expression for CD68 in HPC (p = 0.024)
and increased trends for CD68 in ECX (p = 0.058) (Figure 2I).
Particularly, APP/Arg1 insufficient mice expressed more CD68
in HPC (p = 0.042) and ECX (p = 0.037) compared to APP/Arg1
sufficient mice (Figure 2I). It also showed either trending or
significant main effects of Arg1 insufficiency genotype for IBA1
in ACX (p = 0.07), HPC (p = 0.016) and ECX (p = 0.008) (Figure
2J). The nTg/Arg1 insufficient mice expressed more IBA1 in
ACX (p = 0.025), HPC (p = 0.006) and ECX (p = 0.005)
compared to nTg/Arg1 sufficient mice (Figure 2J). While it is
well known that Ab deposition activates microglia, these data
also suggest that Arg1 myeloid insufficiency generally stimulates
microglial activation.
Arg1 Insufficiency During Amyloidosis
Hastens the Impairment of Mouse
Behavioral Performance
Next, we determined if Arg1 insufficiency impacts behavioral
performance in APP and nTg mice. We used open field behavior
to measure overall activity by total distance traveled and total
immobile time, and anxiety by total time spent in the center
zone. The APP mice were more active relative to nTg mice
measured by increased total distance traveled (p < 0.0001, Figure
3A) and decreased total time immobile (p = 0.001, Figure 3B).
Although we did not find any difference for the time spent in the
center zone in mice with APP, we found that mice with Arg1
insufficiency spent less time in the center, indicating increased
anxiety (p = 0.039, Figure 3C). We measured mouse general
working memory by Y-maze and showed that APP mice
demonstrated a decreased percentage of alternation (p <
0.0001), suggesting decreased working memory with
amyloidosis (Figure 3D). Additionally, we found main effects
in genotypes of APP (p < 0.0001) and Arg1 insufficiency (p =
0.027), as well as an interaction between genotypes in measuring
the number of entries in Y-maze (p = 0.003). Specifically, the
APP/Arg1 insufficient mice displayed an increased number of
entries compared to APP/Arg1 sufficient mice (p < 0.0001),
suggesting APP/Arg1 insufficient mice were more exploratory
(Figure 3E). Furthermore, we tested mice in the radial arm water
maze (RAWM), to measure spatial working memory. Mice
received two days of training using one goal arm followed by 1
day of reversal training (using the opposite arm as the goal arm).
Errors were counted during training until the mouse reached the
rescue platform. Repeated measure ANOVA analysis over three
days showed that mice with APP performed more errors
compared to nTg mice (p < 0.0001, Figure 3F). Examining
each day of training separately revealed that APP mice
successfully learned procedural aspects of the maze so there
were no main genotype effects on Day 1 (p = 0.054) or Day 2 (p =
0.064) of training (Figure 3G). However, APPmice were less able
to learn a new platform location, so there was a main effect of
APP genotype on the reversal day of testing (p < 0.0001, Figure
3G). The total number of errors for APP/Arg1 insufficient mice
was the highest amongst all groups (Figure 3G). Lastly, we
measured aversive conditioning for fear associated memory.
After the initial training trials for all groups, we measured the
aversive conditioning by calculating the percentage of freezing
time during contextual and cued testing. In the context testing,
the APP/Arg1 insufficient mice showed the lowest percentage of
freezing time among all groups, and significantly less than nTg/
Arg1 insufficient mice (p = 0.009), which contributed to the
overall main effect in APP genotype (p = 0.006) (Figure 3H). In
cued testing, all groups of mice showed a higher percentage of
freezing time during the toning phase than the no tone phase,
indicating an association with learning behavior (Figure 3I).
During the toning phase, the APP/Arg1 insufficient mice
demonstrated the weakest freezing response among all groups
and had less total freezing time percentage than nTg/Arg1
insufficient mice (p = 0.009), which accounts for the main
effect in APP genotype (p = 0.002) (Figure 3I). In summary,
mice with amyloidosis display impaired behaviors activities,
anxiety, and memory, while Arg1 insufficiency exacerbated
these effects.
Arg1 Insufficiency Decreases Total
Arginase 1 Expression and Increases
Arginine in Mouse Brain
To determine if hemizygous deletion of Arg1 in myeloid cells
impacts total ARG1 expression and arginine levels in the brain,
we measured Arg1 mRNA by qRT-PCR, ARG1 protein by
western blotting and arginine by LC-MS/MS. Interestingly,
although we did not find changes in Arg1 mRNA between
groups, we detected an overall decreased expression of ARG1
protein by the main genotype effect of Arg1 insufficiency (p =
0.032) (Figures 4A, B, D). We detected a higher level of arginine
in the APP/Arg1 insufficient mice relative to nTg/Arg1
insufficient mice (p = 0.003) and the main effect of APP
genotype (p = 0.036) (Figure 4C). We also observed a trend
for increased arginine comparing APP/Arg1 insufficient mice to
APP/Arg1 sufficient mice (p = 0.095) (Figure 4C). Overall,
hemizygous deletion of Arg1 in myeloid cells modestly
decreased total ARG1 expression and increased arginine levels
during brain amyloidosis.
Ragulator-Rag Complex Critical for
Microglial Phagocytosis Is Increased
During Amyloidosis and Blunted in Arg1
Insufficient APP Mice
Several key studies using different models reported that several
components of the Ragulator-Rag complex, namely LAMTOR2,
LAMTOR3, LAMTOR4, and RAG A were essential regulators for
maintaining normal lysosomal activity and microglial
phagocytosis; loss of functions inhibit phagocytic digestion,
even after engulfment of neuronal debris (38, 39). Therefore,
we measured the expression of LAMTOR2, LAMTOR3,
LAMTOR4, and RAG A by western blot. Densitometry
analysis showed that APP/Arg1 sufficient mice had increased
expression in LAMTOR4 (p = 0.005), RAG A (p = 0.002) and
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increased trend of LAMTOR2 (p = 0.095) and LAMTOR3 (p =
0.053) relative to nTg/Arg1 sufficient mice (Figures 4D–H).
However, this effect was blocked in APP/Arg1 insufficient mice
compared to APP/Arg1 sufficient mice. Importantly, the APP/
Arg1 insufficient mice had reduced expression in LAMTOR2
(p = 0.031), LAMTOR3 (p = 0.001), LAMTOR4 (p = 0.022) and
RAG A (p = 0.012) compared to APP/Arg1 sufficient mice, thus
resulted either trending or significant interactions between APP
and Arg1 insufficiency genotypes on LAMTOR2 (p = 0.098),
LAMTOR3 (p = 0.002), LAMTOR4 (p = 0.008), and RAG A (p =
0.002), respectively (Figures 4E–H). Despite increased microglia
activation measured by IBA1 and CD68, these data strongly
suggest that several components of the Ragulator-Rag complex
are up-regulated during amyloidosis and reduced with Arg1
insufficiency, indicating a potential deficit in microglial
digestion machinery.




FIGURE 3 | Hemizygous deletion of Arg1 in myeloid cells of APP Tg2576 mice adversely affects behavioral performance. We performed mouse behavioral tests to
measure general activity and anxiety in the open field, general working memory in Y-Maze, spatial working memory in Radial Arm Water Maze (RAWM), and fear
associated recall in aversive conditioning. The four groups consisted of: nTg/Arg1+/+/LysMcreTg/+, nTg/Arg1fl/+/LysMcreTg/+, APP+/−/Arg1+/+/LysMcreTg/+, APP+/−/
Arg1fl/+/LysMcreTg/+. (A–C) Total distance traveled (A), total time immobile (B), and time in the center zone (C) were measured and analyzed for open field
assessment. (D, E) Percentage of alternation (D) and the number of entries (E) were measured and analyzed for Y-maze assessment. (F) Average errors performed
by the mice over three days (Day 1, Day 2, and Reversal Day 3) were analyzed for RAWM. (G) Total errors performed by the mice on Day 1, Day 2, and Day 3
(Reversal) were analyzed for RAWM. (H, I) Percentage of total freezing time from context (H) and cued (no tone phase and tone phase) (I) were measured and
analyzed for aversive conditioning assessment. For mice in each group, n = 17 for nTg/Arg1+/+/LysMcreTg/+, n = 22 for nTg/Arg1fl/+/LysMcreTg/+, n = 7–8 for APP+/−/
Arg1+/+/LysMcreTg/+, n = 10 for APP+/−/Arg1fl/+/LysMcreTg/+. Asterisk sign (*) denotes statistical significance observed for the main effect of APP genotype and
associated pairwise comparisons. The number sign (#) denotes statistical significance observed for the main effect of Arg1 insufficiency genotype and associated
pairwise comparisons. Ampersand sign (&) denotes statistically significant interaction between APP genotype and Arg1 insufficiency genotype. */#p < 0.05; **/&&p <
0.01; ****/####p < 0.0001. Two-way ANOVA followed by pairwise comparisons. A repeated measure of two-way ANOVA was performed for RAWM average errors
(G). Values represent mean ± SEM.
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Arg1 Repression and Arginine
Supplementation Impair Microglia
Phagocytosis In Vitro
Two in vitro methods were employed to determine if arginine
metabolism impacts microglia phagocytic function measured by
pHrodo phagocytosis assay. Fluorescent green E. coli bioparticle
conjugates are presented to phagocytic cells and green
fluorescence increases as pH decrease from neutral cytoplasm
to the acidic lysosome. The phagocytic activity of cells is
measured based on the acidification of the bioparticles as they
are ingested by phagosomes (pH 6.1–6.5) and digested by
phagolysosomes (pH 5.0–5.5) (40). We detected green
fluorescence by flow cytometry and calculated the phagocytosis
index (%) based on the percentage of pHrodo green fluorescence.
First, we employed an immortalized rat microglial HAPI cell line
due to high endogenous Arg1 expression. Naïve HAPI cells
without siRNAs and bioparticles served as a negative control
for green fluorescence detected at an average of 0.2% (Figures
5A, B, I). HAPI cells treated with siGLO-Green without
bioparticles was designed as a positive control for measuring
cellular uptake of siRNAs and green fluorescence, which detected
at an average of 100% (Figures 5C, D, I). After treating cells with
bioparticles, cells transfected with non-targeting siRNA (siRNA-
NT) showed an average of 76% phagocytosis index (Figures 5E,
F, I). However, Arg1 siRNA (siRNA-Arg1) transfected cells only
showed a phagocytosis index at an average of 47.3%, much lower
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FIGURE 4 | Hemizygous deletion of Arg1 in myeloid cells reduced total Arg1 and Ragulator-Rag complex components during brain amyloidosis. We measured Arg1
mRNA by qRT-PCR, ARG1 protein by western blotting, and its catabolizing substrate arginine by LC-MS/MS. We also measured key Ragulator-Rag complex
component proteins critical for microglial phagocytosis by western blotting. Mouse brain samples used were comprised of four experimental groups: nTg/Arg1+/+/
LysMcreTg/+, nTg/Arg1fl/+/LysMcreTg/+, APP+/−/Arg1+/+/LysMcreTg/+, APP+/−/Arg1fl/+/LysMcreTg/+. (A) Quantification analysis of qRT-PCR data for Arg1 mRNA that
was normalized to b-actin. (B) Quantification analysis of western blot data for ARG1 protein. (C) Quantification analysis of LC-MS/MS data for amino acid arginine.
(D) Representative images of western blotting for ARG1, LAMTOR2, LAMTOR3, LAMTOR4, and RAG (A) (E–H) Quantification analysis of LAMTOR2 (E), LAMTOR3
(F), LAMTOR4 (G) and RAG A (H) from images in (D). For mice in each group, n = 8–10 for nTg/Arg1+/+/LysMcreTg/+, n=8-10 for nTg/Arg1fl/+/LysMcreTg/+, n=6-7
for APP+/−/Arg1+/+/LysMcreTg/+, n=7-9 for APP+/−/Arg1fl/+/LysMcreTg/+. Asterisk sign (*) denotes statistical significance observed for the main effect of APP genotype
and associated pairwise comparisons. The number sign (#) denotes statistical significance observed for the main effect of Arg1 insufficiency genotype and associated
pairwise comparisons. Ampersand sign (&) denotes statistically significant interaction between APP genotype and Arg1 insufficiency genotype. */#p < 0.05; **/&&p <
0.01; ###p < 0.001. Two-way ANOVA followed by pairwise comparisons. Values represent mean ± SEM.
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than cells transfected with siRNA-NT, suggesting that Arg1
repression impaired phagocytosis in HAPI rat microglial cells
(Figures 5G, H, I). Second, we treated primary rat microglia at
control (basal arginine concentration at 0.7 mM), 3 mM
arginine, and 10 mM arginine in the culture medium followed
with pHrodo phagocytosis assay. Cells were gated for total and
high pHrodo green fluorescence (GFP Total and GFP High)
representing the different extent of phagocytosis activity (Figures
5J–R). Although the average of GFP Total phagocytosis index














FIGURE 5 | Arg1 repression by siRNA and arginine supplementation decreases phagocytosis in rat microglial cells. We transfected siRNAs in HAPI rat microglia
cells with siGLO-Green, non-targeting siRNA (siRNA-NT), Arg1 siRNA (siRNA-Arg1), and performed pHrodo phagocytosis assay. (A–H) Representative flow
cytometry gating analysis is shown in dot plots for naïve cells (A, B), siGLO-Green transfected cells (C, D), siRNA-NT transfected cells (E, F), and siRNA-Arg1
transfected cells (G, H). Naïve cells were not treated with fluorescent green E. coli bioparticle conjugates and served as a negative population for green fluorescence.
Cells transfected with siGLO-Green siRNA were used as positive controls for both siRNA transfection efficiency and green fluorescence. (I) Quantification analysis of
the percentages of green fluorescence from pHrodo phagocytosis assay. pHrodo phagocytosis assay was also performed using primary rat microglia that were
incubated with basal arginine (Control, 0.7 mM), 3 mM arginine, and 10 mM arginine. (J–R) Representative flow cytometry gating analysis is shown in the histogram
and dot plots for the cells from Control (J–L), 3 mM arginine (M–O), and 10 mM arginine (P–R). (S) Quantification analysis of the percentages of pHrodo green
fluorescence (GFP Total and GFP High). (T) Representative overlapping histogram analysis for each condition. Naïve cells were not treated with fluorescent green
E. coli bioparticle conjugates and thus served as a negative population for green fluorescence. n = 2 independent experiments. The average values from each group
are calculated. Values represent mean ± SD.
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(85%) of arginine, the average of the GFP High phagocytosis
index showed larger differences among control (78.4%), 3 mM
(77.8%), and 10 mM (30.5%) of arginine (Figure 5S). Thus, we
observed a dramatic 47.9% reduction in GFP High phagocytosis
index with 10 mM arginine compared to the control condition
(Figure 5S). Interestingly, 3 mM arginine showed an equivalent
GFP High phagocytosis index compared to the control condition
(Figure 5S). A representative histogram of pHrodo green
fluorescence clearly showed only the 10 mM arginine treated
cells had two small peaks of GFP fluorescence, indicating fewer
bioparticles were delivered to the final stage of phagolysosome
(Figure 5T). Collectively, reduced arginine metabolism induced
either by Arg1 repression or arginine supplementation impairs
microglial phagocytosis in vitro.
DISCUSSION
In the present study, we found that the haploinsufficiency of Arg1
in myeloid cells in a mouse model of amyloidosis increased Ab
deposition, activated microglia, and impaired behavioral
performance. Mechanistic studies suggest that impaired
phagocytosis secondary to reduced Arg1 could contribute to
Ab deposition. Overall, we provided evidence that APP/Arg1
insufficiency increased more diffuse Ab deposits measured by
total Ab and Ab 42, and also stimulated microglial activation via
CD68 and IBA1. The Arg1 insufficiency in APPmice precipitated
more behavior impairment evidenced by more anxiety, more
exploratory behavior, and decreased fear associated memory.
Importantly, the Ragulator-Rag complex was activated during
amyloidosis perhaps as a compensatory response to improve
microglial phagocytosis and degradation of Ab. However,
reduced Ragulator-Rag complex in APP mice with Arg1
insufficiency during amyloidosis indicated that arginine
metabolism has an unappreciated role in executing this
function at the level of the lysosome. Finally, we showed in
vitro evidence that decreased Arg1 expression or increased
arginine levels could inhibit microglial phagocytosis.
Collectively, these data support the overall concept that Arg1
insufficiency in myeloid cells exacerbates amyloidosis induced
neuropathology possibly by activating microglia and
impairing phagocytosis.
Two isoforms of arginase consisting of cytosolic ARG1 and
mitochondrial ARG2 were reported to be increased in the frontal
cortex of AD patients (11, 21, 41). Additionally, a rare allele of
ARG2 in males showed increased risk of developing early-onset
AD (21). In AD mouse models of amyloidosis, increased Arg1,
but not Arg2, was associated with Ab deposition (16, 41).
Although using DFMO or L-norvaline inhibited arginase 1 and
2 and reduced amyloid deposition in AD mouse models, these
compounds both non-specifically inhibit other important targets
to reduce amyloid pathology (16, 42). Previously we showed that
overexpression of Arg1 in the CNS of rTg4510 tau transgenic
mice decreased neuroinflammation, reduced tau pathology, and
myeloid Arg1 knockout mice signified a distinct microglial
phenotype that promoted tau pathology (17). This is consistent
with another study that reported Arg1 positive microglia
participated in clearing Ab plaques during IL-1b mediated
inflammatory response (24). In the current study, by using
conditional LysMcre deletion in APP Tg2576 transgenic mice,
we are the first to measure the specific effect of reducing Arg1 in
myeloid cells in responding to amyloidosis. Our results showed
that reduced Arg1 levels in LysM positive cells promoted
amyloidosis in CNS. Therefore, we argued that the Arg1
expression in myeloid cells was predicted to be a compensatory
response to restrict amyloidosis in AD. The Arg1 promoted
the reparative role of macrophages and studies showed
neurodegeneration was accelerated in Arg1 global deletion and
myeloid Arg1 knockout mice (43). However, although there is a
lack of studies in AD mouse models regarding Arg2, Arg2
knockout mice showed neuroprotective effects and reduced
neurodegeneration in acute models of retinal injury (44, 45).
These studies suggest a distinct role of Arg2 in CNS diseases (46).
We also know that knocking out Arg1 was lethal in mice due to
hyperammonemia caused by arginase deficiency, whereas the
Arg2 knockout mice had intact phenotypes and Arg1/Arg2
double knockout mice exhibited the same arginase deficiency
phenotype as the Arg1 single knockout mice (47, 48). Although
myeloid Arg2 was initially reported to be less involved in
immune responses, recent findings suggest that arginase
isoforms in myeloid cells may play crucial regulatory roles in
immune response (49, 50). It remains interesting for future
studies to investigate the immunological role of myeloid
arginase 2 in association with AD.
The lysosome-associated protein CD68 in microglia was often
assumed to represent enhanced phagocytosis upon Ab
stimulation in AD (51, 52). However, recent work identified
lipid droplet accumulating microglia (LDAM) as having
phagocytic deficits but show phagosome maturation among the
top regulated pathways from LDAM transcriptome. Importantly,
LDAM was found to have upregulated endosomal/lysosomal
genes including CD68 in BODIPY positive (lipid droplets)
microglia (53). Other reports showed that the Ragulator-Rag
complex regulates phagocytic flux in zebrafish, and zebrafish
lacking functional Ragulator-Rag complexes (i.e. LAMTOR4,
RAG A) promoted and expanded lysosomal compartments but
were unable to appropriately digest neuronal debris (38).
Therefore, this urges certain caution in the appearance of
increased lysosomal activity/biogenesis or expanded lysosomal
components such as CD68 that may actually indicate improper
system functioning or uncoupling of the phagocytosis/digestion
process. Interestingly, another report identified three members of
the Ragulator complex (LAMTOR2, 3, 4), RAG A, and NRPL2
(GATOR1 complex) as regulators of phagocytosis (39). The
authors showed that CRISPR knockout of Ragulator
components (LAMTOR2, 3, 4) and RAG A inhibited
phagocytosis, whereas knockout of NRPL2 increased
phagocytosis (39). In our study, we found increased
LAMTOR2, 3, 4, and RAG A in APP/Arg1 sufficient mice,
suggesting that Ab deposition induces Ragulator complex
machinery possibly for enhanced phagocytosis. However, Arg1
haploinsufficiency in myeloid cells blocked this induction in APP
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mice. Our in vitro experimental findings also indicated Arg1
suppression via siRNA in microglial cells reduced phagocytosis,
providing potential mechanism for the in vivo findings. One
result of reduced Arg1 is increased arginine. We also
demonstrated that arginine supplementation in primary
microglia reduced phagocytosis. Thus, arginine and Arg1 levels
impact phagocytic/digestive function. Collectively, this argues
that amyloidosis triggers expression in key Ragulator–Rag
complex components critical for lysosomal digestion and that
proper Arg1 function may be required for this response.
Recent studies with microglia/macrophage markers using
single cell RNA-sequencing (scRNA-seq) distinguished brain
resident microglia from CNS infiltrated myeloid cells
(monocytes/macrophages) (54). The Lyz2 gene increases in
active microglial subpopulations particularly during phases of
demyelination/remyelination, and associates with Trem2
independent microglia activation (55, 56). Since the myeloid
marker gene Lyz2 targets both macrophages and microglia, the
observed consequence of exacerbated amyloidosis from the
current study were possibly attributed to the deficiency of Arg1
in both brain resident microglia and CNS infiltrated
macrophages. Furthermore, as one of the earliest groups
utilizing peripheral myeloid cells (monocytes/macrophages) to
restrict amyloidosis in AD mouse models, we and others
discovered that peripheral monocytes/macrophages were
recruited to the sites of Ab deposition in the brain to
phagocytose Ab plaques and oligomers (25, 26, 57). Together
with resident microglia, infiltrated macrophages promoted
degradation of cerebral Ab (58, 59). Recent studies showed
Arg1 played an essential role in efferocytosis of apoptotic cells
in primary microglia/macrophage (60, 61). Consistent with the
previous report, our current study aligns with the phagocytic
process. Therefore, Arg1 in brain myeloid cells may have dual
roles in removing Ab plaques by phagocytosis and apoptotic
neurons through efferocytosis. Nevertheless, future efforts are
warranted to further distinguish the role of Arg1 in brain resident
microglia from infiltrated peripheral macrophages in responding
to amyloid deposition.
In the past several years, emerging studies reported the
antibacterial enzyme lysozyme 2 was also expressed in neurons
in addition to myeloid cells, thus complicating the interpretation
of results using LysM-Cremice in studying CNS diseases (62). In
one study, researchers found LysM-Cre-driven tdTomato
expressed in less than 25% of microglia, but also observed
LysM-Cre-driven MeCP2 expression in neurons from several
brain regions (63). In another study, researchers found LysM-
Cre-tdTomato positive cells were on average account for less
than 30% in both microglia and neurons, but could be exclusively
expressed in neurons in certain brain regions (64). Most recently,
LysM-Cre-tdTomato was confirmed to efficiently target nearly
40% of microglia/macrophages and surprisingly found to also
target nearly 10% of neurons (65). Therefore, the expected LysM-
Cre specificity in microglia/macrophages and the unexpected
LysM-Cre specificity in neurons indicate two limitations in the
current study. Indeed, both neurons and microglia are critically
involved in AD pathogenesis.
Firstly, all four groups of mice shared the same LysMcreTg/+
genetic background in which the endogenous Lyz2 gene was
disrupted due to the insert of Cre recombinase (66). The
lysozyme was previously reported to show protective properties
in amyloid pathology by interacting with Ab species to reduce Ab
aggregation, and localizing in sites of Ab plaques in AD brains (67–
69). The lysozyme level was also found increased in the CSF of AD
patients, presumably produced mainly by brain myeloid cells (67).
This assumption was recently confirmed by studying Ab plaque-
associated microglia using scRNA-seq. Converging studies pointed
out that Lyz2 was one of the commonly induced microglial genes
by disease-associated microglia (DAM) and microglial
neurodegenerative phenotype (MGnD), suggesting the microglial
expression of Lyz2 played an important role in responding to Ab
stimulus in AD mouse models of amyloidosis (55, 70, 71). These
findings argue that Lyz2 gene is mainly expressed in CNS myeloid
cells rather than other CNS cells, which could be confirmed in the
summarized RNA-seq data website “The Myeloid Landscape 2”
(72). Purified CNS cell types showed both human Lyz and mouse
ortholog Lyz2 only significantly expressed in CNS myeloid cells
rather than other CNS cell types including neurons (GSE73721,
GSE52564, GSE75431). It remains unknown if one allele deletion
of Lyz2 in our study impacts the function of DAM/MGnD
microglial signatures in reacting to amyloidosis. However, the
same Lyz2 deficient genotype shared with all mouse groups
further lessens this concern.
Secondly, although the exact function of Lyz2 in neurons is
not clear and Lyz2 is not dominantly expressed in neurons, we
cannot exclude the fact that LysM-Cre recombination reduced
Arg1 expression in neurons to a certain extent in our study.
Previously we reported that overexpressing Arg1 through
pseudotyped AAV9 with neuronal tropism in the hippocampus
of rTg4510 tau transgenic mice decreased several neuronal tau
pathologies and suggested to increase autophagy through
decreased mTORC1 signaling (17). One reason is that
overexpression of Arg1 could deplete cellular arginine and
eventually decrease arginine sensing mTORC1 activation. In
the current study, we inferred that decreased Arg1 in LysM-Cre
neurons could accumulate cellular arginine to activate mTORC1
signaling by arginine sensing mechanisms, thus inhibit
autophagy activities. Reduced autophagy in neurons had
decreased capacity to degrade intracellular Ab aggregates,
further exacerbated the amyloid pathology in conjunction with
Arg1 deficient myeloid cells. For future studies, myeloid specific
mouse models like Cx3cr1-CreERT2 and Tmem119-CreERT2
should be applied to target monocytes/macrophages and
resident microglia, respectively (73–75).
Although arginine and Arg1 comprise of a general arginine
metabolism pathway, based on the recent identification of amino
acid sensors and signaling components, it remains possible that
arginine and Arg1 act through different mechanisms to affect
phagocytosis and degradation. For example, differential
mechanisms could result from cytoplasmic arginine depletion/
repletion, lysosomal acidification, and GPCR extracellular
signaling; however, further studies are required to elucidate
whether these emerging pathways converge or remain
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independent. Key findings reported arginine signaling through
the lysosomal transporter SLC38A9-Ragulator-Rag-mTORC1
axis and CASTOR1-Ragulator-Rag-mTORC1 axis, both of
which activate downstream mTORC1 signaling and inhibit
autophagy (76). In our study, APP/Arg1 insufficient mice
showed increased CD68 expression in HPC and ECX
compared to APP/Arg1 sufficient mice and nTg/Arg1
insufficient mice, suggesting that amyloidosis and Arg1
deficiency promoted CD68 expression. However, given the
relationship between ARG1-arginine and arginine-Ragulator-
Rag-mTORC1-axis, it is possible that myeloid-specific
demands for Arg1 are required in response to amyloidosis and
that uncoupling of phagocytosis/digestion initiates increased Ab
deposition. During certain types of inflammation, myeloid/
microglia cells launch iNOS and Arg1 temporally, spatially or
even simultaneously, which is thought to provoke either M1 or
M2 phenotype to facilitate the clearance of debris and would
repair (77). Given this, both enzymes deplete arginine levels,
which could essentially promote phagocytosis from both pro and
anti-inflammatory states. However, the balance of these enzymes
in myeloid/microglial cells in response to amyloidosis may be
critical in precipitating the AD phenotype. This is evident in
work by Kan et al., which argues that excessive Arg1 also
promotes amyloidosis in a NOS2 null background (16).
Probably, Arg1 and NOS2 activities, their respective
byproducts, and arginine depletion/repletion are temporally
critical regarding microglial response to amyloidosis.
Overall, our findings imply that the haploinsufficiency of Arg1
in myeloid cells during amyloidosis exacerbates AD-like
neuropathology, neuroinflammation, and behavioral deficits. It
remains unclear as to the exact mechanism of how Arg1 or
arginine governs phagocytic-digestive function. However,
emerging evidence may suggest arginine signaling to
mTORC1. Sustained Arg1 would essentially deplete local
arginine levels permitting activation of autophagy through
mTORC1 inhibition. Therefore, proper Arg1 levels in
microglia/myeloid cells become critical for activating
phagocytic responses during challenges such as amyloidosis.
While failure to mount sustained Arg1 during the Ab challenge
could result in local arginine accumulation and phagocytic
dysfunction. Importantly, arginine sensors could serve as new
therapeutic targets to rebalance failed phagocytic function during
amyloidosis or other disorders associated with immune function.
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control) showed increased arginase activity post IL-4 treatmentwith orwithout LPS
(p < 0.0001); however, macrophages of nTg/Arg1fl/fl/LysMcreTg/+ mice did not
induce arginase activity in both conditions. In addition, in IL-4 treatment with or
without LPS co-stimulation, primary macrophages isolated from nTg/Arg1fl/fl/
LysMcreTg/+mice showed decreased arginase activity compared tomacrophages
from either nTg/Arg1+/+ mice (p < 0.0001) or nTg/Arg1fl/fl mice (p < 0.0001). n = 3
independent replicates from three independent biological replication experiments.
(B) In measuring Neuro-2a viability using macrophage conditioned medium
(MCM), neuroprotection drug azithromycin (AZM) co-incubation with LPS/IFN-g
increased neuron viability compared to LPS/IFN-g stimulation, a phenomenon only
observed using MCM from nTg/Arg1+/+ mice (p < 0.0001), but not in nTg/Arg1fl/fl/
LysMcreTg/+ mice. In addition, AZM co-incubation with LPS/IL-4 showed
increased trend in neuron viability than LPS/IL-4 stimulation using MCM from nTg/
Arg1+/+ mice (p = 0.051), but not in nTg/Arg1fl/fl/LysMcreTg/+ mice. n = 10
independent replicates from three independent biological replication experiments.
****, p < 0.0001; n.s. (not significant), p > 0.05. Two-way ANOVA followed by
multiple comparisons with Dunnett’s or Sidak’s post-hoc tests. Values represent
mean ± SEM.
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